Thank you, Mr. Chair.
I am curious about the waiver of fees for pediatrics. It would seem that would be a reasonable approach—when the company may be making no profits in other divisions, that it wouldn't consider that as the loss leader for brand development, and so forth.
Is it the fees so much so that it basically makes it non-competitive? If we have a low market here—despite Ontario being one of the largest consumer commercial markets in North America compared to many states—just waiving the fees or the regulations would make the difference for putting drugs on the market. Do you have an example of that, that we could pull for this study? That would be really interesting.